On Tuesday, the European Commission approved the antibody lecanemab for treating Alzheimer’s disease.
Lecanemab is designed for use during the initial phases of the condition, and it marks the first approval of such a drug within the European Union, according to the Commission.
This marks the first instance where the European Commission has approved an Alzheimer’s treatment aimed at tackling the root causes of the condition instead of merely addressing its symptoms.
Nevertheless, specialists indicate that just a tiny fraction of Alzheimer's patients qualify for this treatment.
Lecanemab is marketed as Leqembi. This medication has already received approval in the United States, the UK, and Japan.
More to come...
Author: Kalika Mehta (in collaboration with DPA)